
Health · 20 November 2026
Europe authorizes Rasonque as pancreatic cancer treatment extends survival
For previously treated patients, Revolution Medicines’ drug delivered 76.6% survival at one year, compared with 40–45% for chemotherapy alone.
France, Europe and the world.

For previously treated patients, Revolution Medicines’ drug delivered 76.6% survival at one year, compared with 40–45% for chemotherapy alone.